FAQ/Help |
Calendar |
Search |
Today's Posts |
01-02-2015, 09:08 AM | #1 | ||
|
|||
Member
|
|
||
Reply With Quote |
"Thanks for this!" says: | lab rat (01-02-2015) |
01-02-2015, 09:29 AM | #2 | ||
|
|||
Magnate
|
gotta wonder if insurance companies are going to pay for the incredibly expensive carbidopa/l-dopa that they use, if it's anything close to what is used in the duodopa pump, which has not yet been approved in the U.S., the cost could be well over $25,000/year. plus i assume you'll have the same problems with protein interference with l-dopa passing thru the BBB that you get with oral l-dopa
i may be wrong but sure seems like a better agonist in a controlled release form with fewer side affects would be a better solution than a pump, and the current options mirapex-xl, requip-xl and the neupro patch are too expensive imho. i'm glad this will be an option, just thinking out loud. |
||
Reply With Quote |
"Thanks for this!" says: | lab rat (01-02-2015) |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
NeuroDerm Announces Positive Topline Results of Phase II Trials | Parkinson's Disease | |||
NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development o | Parkinson's Disease | |||
ND0611 Neuroderm sees promising data | Parkinson's Disease Clinical Trials | |||
NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development o | Parkinson's Disease | |||
NeuroDerm, Ltd. announced today the successful enrollment and dosing in its Phase I c | Parkinson's Disease |